Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

Effective treatment with dupilumab may allow younger children with severe atopic dermatitis and short stature to catch up on ...

A new study published in the Journal of American Academy of Dermatology found that Dupilumab improved atopic dermatitis (AD) ...

Moreover, diabetes was linked with a nearly fourfold increase in pulmonary fibrosis among patients with RA (OR 3.704, 95% CI ...

Barbara Paldus is the founder of biotech company Codex Labs and an expert on all things skincare, skin health and skin ...

The following is a summary of “Clinical Effectiveness and Safety of Dupilumab in Chronic Obstructive Pulmonary Disease ...

Dupilumab, an injectable interleukin (IL)-4 and IL-13 pathway inhibitor, recently received FDA approval as the first-ever ...

Kymera Therapeutics Inc. has received IND clearance from the FDA for KT-621, an investigational first-in-class, once-daily, oral STAT6 degrader.

Learn how dupilumab significantly improves quality of life in COPD patients with type 2 inflammation, according to phase 3 ...

In a major potential step toward personalized therapy for atopic dermatitis, data suggest early, late, and no clinical ...

The separation of Ebglyss from Dupixent and Adbry/Adtralza will depend on real-world clinical benefits, patient experience ...

Less frequent dosing could provide Eli Lilly’s Ebglyss room to rival Sanofi and Regeneron’s blockbuster Dupixent.